First Trust Advisors
RPRX icon

First Trust Advisors’s Royalty Pharma RPRX Stock Holding History

First Trust Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$47.8M Buy
852,412
+66,017
+8% +$3.44M 0.03% 637
2026
Q1 		$37.7M Sell
786,395
-59,150
-7% -$2.59M 0.03% 686
2025
Q4 		$32.7M Buy
845,545
+61,939
+8% +$2.36M 0.02% 734
2025
Q3 		$27.6M Sell
783,606
-320,438
-29% -$11.6M 0.02% 791
2025
Q2 		$39.8M Sell
1,104,044
-495,192
-31% -$16.4M 0.03% 658
2025
Q1 		$49.8M Buy
1,599,236
+800,728
+100% +$25.4M 0.04% 535
2024
Q4 		$20.4M Sell
798,508
-157,472
-16% -$4.18M 0.02% 854
2024
Q3 		$27M Buy
955,980
+51,544
+6% +$1.43M 0.03% 696
2024
Q2 		$23.8M Buy
904,436
+879,632
+3,546% +$24.4M 0.02% 723
2024
Q1 		$753K Sell
24,804
-161,392
-87% -$4.76M ﹤0.01% 2049
2023
Q4 		$5.23M Buy
186,196
+171,249
+1,146% +$4.71M 0.01% 1237
2023
Q3 		$406K Buy
+14,947
New +$444K ﹤0.01% 2188
2023
Q2 		– Sell
-10,462
Closed -$377K – 2434
2023
Q1 		$377K Sell
10,462
-118,157
-92% -$4.38M ﹤0.01% 2192
2022
Q4 		$5.08M Sell
128,619
-18,751
-13% -$783K 0.01% 1187
2022
Q3 		$5.92M Sell
147,370
-164,748
-53% -$7.04M 0.01% 1123
2022
Q2 		$13.1M Buy
312,118
+2,236
+0.7% +$91.7K 0.02% 855
2022
Q1 		$12.1M Sell
309,882
-182,912
-37% -$7.18M 0.01% 985
2021
Q4 		$19.6M Buy
492,794
+37,900
+8% +$1.47M 0.02% 847
2021
Q3 		$16.4M Sell
454,894
-32,128
-7% -$1.25M 0.02% 846
2021
Q2 		$20M Sell
487,022
-52,884
-10% -$2.25M 0.02% 777
2021
Q1 		$23.6M Sell
539,906
-67,209
-11% -$3.19M 0.03% 656
2020
Q4 		$30.4M Buy
+607,115
New +$25.8M 0.04% 514

Other funds holding RPRX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

First Trust Advisors's RPRX Position: Q2 2026 in Review

First Trust Advisors increased its Royalty Pharma (RPRX) stake by 8.4% in Q2 2026, buying an estimated $3.44M and bringing the position to 852,412 shares worth $47.8M. The position accounts for 0.03% of the portfolio, ranked #637.

First Trust Advisors first reported a position in RPRX in Q4 2020 and has held it in 22 quarters since. The position peaked at $49.8M in Q1 2025. 645 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • First Trust Advisors held 852,412 shares of Royalty Pharma worth $47.8M as of Q2 2026.
  • First Trust Advisors bought 66,017 Royalty Pharma shares in Q2 2026, an estimated $3.44M.
  • Royalty Pharma made up 0.03% of First Trust Advisors's portfolio in Q2 2026, its #637 holding.
  • First Trust Advisors first reported a position in Royalty Pharma in Q4 2020 and has held it in 22 quarters since.
  • First Trust Advisors's Royalty Pharma position peaked at $49.8M in Q1 2025.
  • 645 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on First Trust Advisors's 13F filing for Q2 2026, filed 11 Aug 2026.